claim
Posted by admin
•
September 24, 2026 at 04:00 PM
The FDA should use expedited pathways only for diseases with no existing treatments, not for competitive market categories.
Vote to see results
Responses & Discussion
Log in to add your response to this statement
Log InNo responses yet. Be the first to share your perspective!